# Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

> **NCT01046864** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 49 (actual)

## Conditions studied

- Gastro-Intestinal Cancer

## Interventions

- **DRUG:** 5-FU
- **DRUG:** Leucovorin
- **DRUG:** 5-FU
- **DRUG:** Irinotecan
- **DRUG:** Brivanib
- **DRUG:** Brivanib
- **DRUG:** Brivanib

## Key facts

- **NCT ID:** NCT01046864
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2014-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01046864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01046864, "Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01046864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*